WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

                Date of Report (Date of earliest event reported):
                                   May 3, 2001

                                 PERRIGO COMPANY
               (Exact name of registrant as specified in charter)

    MICHIGAN                      0-19725                      38-2799573
 ---------------                ------------              -------------------
 (State of other                (Commission                (I.R.S. Employer
 Jurisdiction of                File Number)                Identification
  Incorporation)                                                Number)

515 Eastern Avenue, Allegan, Michigan                   49010
------------------------------------------           -----------
(Address of principal executive offices)              (Zip Code)

Registrant's telephone number, including area code:
(616) 673-8451


         ITEM 5.  Other Events

         Government Regulations - Food and Drug Administration

                  On May 2, 2001, the Company was notified by the FDA Detroit
         District Office that it has recommended that Abbreviated New Drug
         Applications (ANDAs) for two of the Company's products be approved for
         manufacturing at its Allegan, Michigan facility. This recommendation
         grew out of an FDA inspection and follow-up review that was conducted
         in March 2001, following the FDA's issuance of a Warning Letter in
         August 2000. It is now anticipated that final approval of the Company's
         ANDAs will not be withheld due to issues identified in the August 2000
         Warning Letter.

                  In August 2000, the Company received a Warning Letter from the
         FDA primarily related to manufacturing issues identified during the
         FDA's April 2000 inspection of its Allegan facilities. The Warning
         Letter also identified certain issues related to the Company's Quality
         Systems. In response to the Warning Letter, the Company met with the
         FDA to discuss the manufacturing and Quality Systems issues. The
         Company is implementing remedial action to address the manufacturing
         issues and has completed a Global Improvement Plan (GIP) with the help
         of outside consultants to ensure that the Company's Quality Systems
         comply with "Current Good Manufacturing Practices" (cGMP) on an
         on-going basis. The GIP Plan includes a review of the Quality Systems,
         formulation of revisions to the Quality Systems, a plan to implement
         identified changes and a plan to audit and measure the effectiveness of
         the corrective action taken. The Company has already taken
         comprehensive corrective action as outlined in the GIP Plan and will
         continue to implement the GIP Plan on an on-going basis to ensure
         compliance with cGMP.

                  The manufacturing, testing, packaging, distribution, labeling,
         advertising and sale of the Company's products are subject to
         regulation by one or more United States agencies, including the FDA.
         The FDA exercises authority over three aspects of the Company's
         business: (i) the operation of manufacturing, testing and packaging
         facilities, (ii) the labeling and marketing of over-the-counter (OTC)
         pharmaceutical drug products, and (iii) the labeling and marketing of
         dietary supplements.

                  On an on-going basis, the FDA reviews the safety and efficacy
         of OTC pharmaceutical products and monitors the labeling, advertising
         and other matters related to the promotion and sale of such products.
         The FDA also regulates the facilities and procedures used to
         manufacture OTC pharmaceuticals and all facilities must be registered
         with the FDA and all products made in those facilities must be
         manufactured in accordance with cGMP established by the FDA. Compliance
         with cGMP guidelines entails a dedication of substantial resources and
         requires significant costs.

                  The FDA performs periodic inspections to ensure that the
         Company's facilities remain in compliance with cGMP regulations. The
         failure of a facility to be in compliance may lead to regulatory action
         that could result in production interruptions, product recalls or
         delays in new drug approvals. The impact of one or more of these
         actions could have a material adverse effect on the Company's business.



                  Pursuant to the requirement of the Securities Exchange Act of
         1934, the registrant has duly caused this report to be signed on its
         behalf by the undersigned hereunto duly authorized.

                                          PERRIGO COMPANY

                                          By: /s/ Douglas R. Schrank
         Dated: May 3, 2001                       Douglas R. Schrank
                                                  Executive Vice President and
                                                  Chief Financial Officer